Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Aethlon Medical ( (AEMD) ) just unveiled an update.
Aethlon Medical, Inc. has reported significant advancements in its oncology trials, enrolling the first two patients in its Hemopurifier® study for those with solid tumors not responding to anti-PD-1 antibodies. The company has also opened two sites in Australia for patient enrollment and received ethics approval for a trial in India. Aethlon is focusing on strategic cost-cutting measures and optimizing resources to support high-impact trials, aiming to enhance therapeutic responses and expand its Hemopurifier’s use against viral infections.
For detailed information about AEMD stock, go to TipRanks’ Stock Analysis page.
